Header image
![](/sites/default/files/styles/page_header_image/public/2023-07/foto_zahlavi_research_1.jpg?itok=p7pBtlZR)
Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer
Utilization of fluorescence in situ hybridization with cytokeratin discriminators in TOP2A assessment of chemotherapy-treated patients with breast cancer.
Human Pathology.
2012,
43(9),
1363-1375,
ISSN: 0046-8177,
PMID: 22204715,